Coventry-Based Biotech Grabs £6.2M Funding To Develop Its Novel Biologic Delivery Platform
07/19/21, 10:59 AM
Location
Money raised
£6.2 million
Coventry-based biotech, NanoSyrinx has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA.
Company Info
Company
Coventry Based
Location
coventry, rhode island, united states
Additional Info
The company will use this investment to fully investigate the applications of its technology across a range of therapeutic indications and novel modalities. Proof-of-concept studies both for in vivo active pharmaceutical delivery and ex vivo cell engineering will be undertaken to better understand the optimal clinical targets and to build a pipeline of programmes to take forward in the next phase of growth.Dr Joe Healey, CEO of NanoSyrinx, commented: “We’re thrilled that all our current investors have recognised the tremendous progress made by the company in 2020 and have chosen to continue supporting us.